Spark Therapeutics and Pfizer announce hemophilia B data showing sustained factor IX level
Spark Therapeutics and Pfizer announced all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe hemophilia B, had discontinued routine infusions of factor IX concentrates. None of the 15 participants experienced serious adverse events. May 22, 2018